AlphaStocks
2.7
Avoid

Supernus Pharmaceuticals, Inc. (SUPN)

As of Sep 20, 2026, Supernus Pharmaceuticals, Inc. (SUPN) scores 2.7/10 on AlphaStocks' five-model composite, #162 of 168 Health Care stocks. At $42, SUPN trades 38% above its model fair value of $30.

Health Care / Pharmaceuticals

S&P SmallCap 600

$41.96

Scores poorly across most models. Proceed with caution.

Avoid

Score based on 4 of 5 models — moderate confidence

Data as of Sep 20, 2026

#162out of 168 in Health Care

Is SUPERNUS PHARMACEUTICALS, INC. a Good Investment in 2026?

SUPERNUS PHARMACEUTICALS, INC. (SUPN) scores 2.7 out of 10 on AlphaStocks' composite model, earning a Avoid rating. The Lynch model rates SUPERNUS PHARMACEUTICALS, INC. as Attractive. However, the Greenblatt Magic Formula model rates it Caution — Earnings yield -2.4% · ROC -20%. SUPERNUS PHARMACEUTICALS, INC. currently trades 38% above its estimated fair value of $30. SUPERNUS PHARMACEUTICALS, INC. ranks #162 out of 168 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

ROE-3.7Market Cap2B

Estimated Fair Value

$30.3038% above

Trading above estimated fair value — the market may be pricing in future growth.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Neutral

4/9

Buffett

Neutral

Business quality & competitive moat

Graham

Caution

Price vs intrinsic value

Lynch

Attractive

Growth rate vs price (PEG)

Greenblatt

Caution

Earnings yield -2.4% · ROC -20%

Frequently Asked Questions

Is SUPERNUS PHARMACEUTICALS, INC. (SUPN) a good investment?
As of Sep 20, 2026, Supernus Pharmaceuticals, Inc. (SUPN) scores 2.7/10 on AlphaStocks' five-model composite, #162 of 168 Health Care stocks. At $42, SUPN trades 38% above its model fair value of $30. That score is below average, suggesting caution.
What is SUPERNUS PHARMACEUTICALS, INC.'s Piotroski F-Score?
SUPERNUS PHARMACEUTICALS, INC.'s Piotroski F-Score status is Neutral. The raw score is 4/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is SUPN overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $30, SUPN appears overvalued. The stock currently trades 38% above its estimated fair value. Trading above estimated fair value — the market may be pricing in future growth.
How does SUPN compare to other Health Care stocks?
SUPERNUS PHARMACEUTICALS, INC. ranks #162 out of 168 stocks in the Health Care sector, placing it in the top 96% of its sector by composite score. There are higher-ranked alternatives in this sector worth exploring.
What do investment models say about SUPN?
AlphaStocks evaluates SUPN using five proven investment models. Piotroski: Neutral; Buffett: Neutral; Graham: Caution; Lynch: Attractive; Greenblatt Magic Formula: Caution. These models are combined into a single composite score of 2.7/10.

Similar Stocks

AMPHLLYACAD

Compare SUPN with

AMPH vs SUPNLLY vs SUPNACAD vs SUPN

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer